Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310

Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Biogen (NASDAQ: BIIB) and increased the price target from $250 to $310. This adjustment reflects a positive outlook on the company's performance.